Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Sep 15, 2025

BUY
$0.97 - $1.75 $173,512 - $313,038
178,879 New
178,879 $313,000
Q2 2024

Aug 12, 2024

BUY
$1.79 - $2.8 $320,193 - $500,861
178,879 New
178,879 $320,000

Others Institutions Holding RGLS

About Regulus Therapeutics Inc.


  • Ticker RGLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,634,400
  • Market Cap $119M
  • Description
  • Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-thre...
More about RGLS
Track This Portfolio

Track Charles Schwab Investment Management Inc Portfolio

Follow Charles Schwab Investment Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.